Pfizer boosts China presence with US$350m biotech plant
Facility to be completed in 2018, will make biologics and cheaper versions
Beijing
PFIZER Inc will invest US$350 million in eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.
The new facility in eastern Hangzhou city is expected to be completed in 2018 and will manufacture biologics, or complex medicines made from living organisms, as well as cheaper copycat versions known as biosimilars for patients in China and across the world, Pfizer said in an e-mailed statement Tuesday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue